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ABSTRACT
Objective: The aim of the study was to determine the cost-effectiveness,
from the third-party payer viewpoint, of galantamine compared with usual
care in the treatment ofmild tomoderately severe Alzheimer’s disease (AD).
Methods: An existing Markov model was adapted to Korea to predict
long-term outcomes over a 5-year time horizon and to estimate the cost-
effectiveness of galantamine for the treatment of AD. The model structure
is informed by a review of national and international literature on the
clinical and cost-effectiveness of galantamine and on the costs and out-
comes associated with treatment for AD. The main outcome measure used
was the cost per quality-adjusted life year (QALY) gained. All costs were
indexed to US$ (2007 value). Multivariate probabilistic sensitivity analysis
and scenario analysis were undertaken to assess uncertainty in the results.
Results: The study ﬁndings indicate that the clinical beneﬁts on AD pro-
gression from galantamine treatment resulted in an incremental cost
per QALY gained of US$4939 over 5 years (vs. usual care). Probabilistic
sensitivity analysis and cost-effectiveness acceptability curve suggest that
the probability of galantamine treatment having an incremental cost per
QALY over US$6740 is zero. Incremental cost per QALY gained according
to scenario analyses ranged from US$2271 to US$8335.
Conclusion: These ﬁndings suggest that the use of galantamine may be a
cost-effective use of Korean national health-care resources, considering the
gross domestic product per capita of US$21,695 in 2007.
Keywords: Alzheimer, cost-effectiveness, galantamine, Korea.
Introduction
Alzheimer’s disease (AD) is the most common cause of dementia
in Korea [1]. AD is placing substantial medical, social, psycho-
logical, and ﬁnancial burdens on patients, their families, and
their communities. The number of dementia patients in Korea is
estimated over 400,000 in 2008, and projected over 1 million in
2030 [2]. As opposed to people with mild physical handicaps,
people affected by even mild dementia need assistance and some
surveillance. Moreover, people suffering from severe dementia
require high-level, specialized care. AD progresses dramatically.
In 3 years, 54% of people affected by AD reached the severe stage
as according to the Clinical Dementia Rating Scale (CDR) [3].
Community-based care for patients with dementia is an explicit
policy preference today. Community services are an essential part
of living with dementia. They are necessary in order to impact
positively on the quality of life of both people with dementia
maintaining their independence and dignity, and the caregivers
who need support with and respite from the duties of caring.
Residential care services are also a necessary part of the con-
tinuum of services for people in the more advanced stages of
dementia. Current economic pressures on available resources and
especially concerns about the future resource pressures have
attracted growing attention on the costs and cost-effectiveness of
prescribed Alzheimer’s drugs and community and residential
care.
In Korea, cognitive impairment is ﬁrst recognized by family
members. They usually bring this problem to the attention of a
specialist such as geriatric psychiatrist, geriatrician, or neurolo-
gist. More than 95% of physicians in Korea are board-certiﬁed,
so that very few general physicians are working. Therefore,
primary contact of patients is a specialist, not a general practi-
tioner. The Mini-Mental State Examination is widely used for
dementia screening. If the screening test is positive, referral is
often made to further diagnostic workup including neuropsycho-
logical test battery, laboratory screening, and brain imaging.
Usually, after the diagnosis is established, internal referrals are
made to a social worker, rehabilitation specialist or to a clinical
trial program as well as clinical treatment by a specialist. Day
care services are provided by community-based dementia centers,
while residential care services are by nursing homes. Long-term
care insurance scheme has provided both community and resi-
dential care services. Moderate cases with behavioral and psy-
chological symptoms of dementia are treated with the addition of
atypical neuroleptics usually, and only in severe cases are patients
referred for day care or nursing home care. In Korea, the
announced criteria for reimbursement of the cholinesterase
inhibitors (i.e., donepezil, galantamine, and rivastigmine) require
speciﬁc conditions (i.e., Mini-Mental State Examination score
10–26 plus CDR 1–2 or Global Deterioration Scale 3–5).
Galantamine is a cholinesterase inhibitor with a dual mode of
action [4]. Clinical trials have shown galantamine to be effective
and safe up to at least 3 years of treatment, and the drug was well
tolerated [5–8].
Currently, no studies have assessed the long-term cost-
effectiveness of galantamine in Korea. This study aims to deter-
mine the cost-effectiveness of galantamine in the treatment of
mild to moderately severe AD over a 5-year time horizon by
estimating costs and outcomes associated with galantamine treat-
ment for AD compared with those of usual care with no Alzhe-
imer’s drugs under the health-care system in Korea.
Methods
A cost-utility analysis was performed to examine the potential
beneﬁts of galantamine to people with AD, and thus calculates
the incremental cost per quality-adjusted life year (QALY) gained
by the introduction of galantamine compared to usual care
without any Alzheimer’s drugs. This economic evaluation was
performed from the third-party payer viewpoint.
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The terms “galantamine OR reminyl” AND “Alzheimer”
were searched, which were limited by “clinical trial” in Medline,
Embase, and the Cochrane Database of Systematic Reviews, and
some scientiﬁc databases in Korea (i.e., KMBASE [http://kmbase.
medric.or.kr], KoreaMed [http://www.koreamed.org], Medical
Library Information System [http://medlis.riss4u.net], Research
Information Center for Health [http://richis.org], Korean Studies
Information Service System [http://kiss.kstudy.com], and Natio-
nal Assembly Library [http://www.nanet.go.kr]). Additionally
the bibliographical data of all included publications were
checked for further studies. All included papers presented origi-
nal data of clinical trials on the use of cholinesterase inhibitors
for the treatment of AD, covering clinical effectiveness, economic
evaluations, modeling methods, health-related quality of life, and
resource use. The clinical, epidemiological, and economic data
from Korean literature were preferred to inform the cost-utility
analysis presented in this article [9–15]. When no data were
found in Korean national literature, data in other countries were
considered and the most frequently quoted ones in previous
publications were chosen.
Costs
Cost data were primarily adopted from a 1-year prospective trial
assessing clinical and economic beneﬁts of galantamine in Korea,
using, as a primary endpoint, proportion of AD patients who
needed full-time care (FTC) after 1 year. The study has been
described in detail elsewhere [10]. In brief, they collected data on
the resource use of all medical and other community service to
estimate costs. Resource use was measured using the adapted
version of the Client Service Receipt Inventory [16]. Primary
caregivers were asked to provide details of services and costs that
patients had used during the previous 2 months by face-to-face
interview. Resources used included hospital and primary care
services (inpatient, outpatient, day hospital, emergency room,
community mental health center, general practitioner, commu-
nity practice nurse, and medication), social care services (social
worker, day care center, meals on wheels, and home care),
accommodation, out-of-pocket purchase for self-support (private
hire of a paid caregiver or a paid home helper, health food and
supplement, etc.), caregiver time, and missed work of caregiver.
Indirect costs were calculated using a replacement cost approach.
Caregiver time was assessed using the caregiver time section of
the Resource Utilization in Dementia questionnaire [17]. Infor-
mal caregiver time was valued at the 2002 average household
help wage in Korea, equivalent to US$5.22 per hour [18]. The
total costs were calculated by adding each cost for resource used
by each patient. Unit costs for 2002 were obtained from national
sources in Korea [19–22]. They reported that average annual
costs per dementia patient who was either in pre-FTC or in FTC
were US$6388 and US$7623, respectively. Full drug cost of
galantamine 24 mg per day was assumed, so that monthly drug
cost was US$173.3 in 2007 value. A report from the National
Health Insurance Corporation in ﬁscal year of 2005 included the
monthly cost of outpatient of US$30.6 in 2004 value [23]. All the
costs used in the model are in 2007 values after conversion using
the ratio of consumer prices index (e.g., value at 2007/value at
2002). For probabilistic sensitivity analyses, parameter distri-
bution should be determined. Cost usually shows left-skewed
distribution. Gamma distribution possibly provides similar left-
skewed distribution.
Effectiveness
The effectiveness data were primarily adopted from results of
intent-to-treat analysis of the 1-year longitudinal study demon-
strated that a signiﬁcantly higher frequency of FTC in the usual
care group (22.2% after 52 weeks) than in the galantamine
treatment group (5.4% after 52 weeks) [10].
Model Structure
The serious challenge when modeling cost-effectiveness of Al-
zheimer’s drugs is predicting disease progression and thereafter
modifying disease progression based on the clinical beneﬁts from
treatment. The methods available to model disease progression
have all raised serious concerns. The prime concern is the use of
cognitive function as a proxy parameter to model disease pro-
gression, which was greatly criticized [24,25]. Therefore, cogni-
tive function has not been used to model disease progression in
this article. The Assessment of Health Economics in Alzheimer’s
Disease (AHEAD) model was adapted in Korea to assess the
economic impact of galantamine treatment, based on the need
for FTC. FTC was deﬁned as the consistent requirement for a
signiﬁcant amount of time (>16 h/day) for care and supervision,
regardless of the locus of care or who provided the care. Origi-
nally, the AHEAD model used predictive equations to estimate
the time until a state for FTC or death [26]. The predictive
equation for FTC and death was not adopted in this study
because we could ﬁnd data on the FTC and mortality in pub-
lished Korean literature [27–29]. Unpublished data on mortality
were also provided by a Korean researcher who has conducted a
longitudinal community cohort study. A common mortality rate
(= 1.138%/month) for all patients was applied in this study.
Although it is accepted that there may be differences in mortality
by age and severity, the data do not allow us to differentiate by
these groups at the moment.
Markov models are particularly useful when a decision
problem involves clinical changes that are ongoing over time. At
any stage of AD, the patient may become sufﬁciently disabled to
require FTC for almost all days. Treatment may modify the AD
progression by slowing the rate of developing disability. In this
Markov model to project the costs and utilities of AD over a
5-year time horizon, three states were supposed: 1) state before
FTC required (pre-FTC); 2) state for FTC; and 3) death. Figure 1
presents an outline of the modeling. Markov Monte Carlo simu-
lation was used to predict time to FTC and to death. In a
ﬁrst-order simulation, 1000 trials were performed to get an
acceptably low level of error with half-cycle correction for both
initial and ﬁnal costs and utilities.
The main assumptions made in the model are as follows: 1)
galantamine would have no impact on survival; 2) for the model
Figure 1 The state transition diagram of cost-effectiveness Markov model for
galantamine compared with usual care. FTC, full time care.
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over a 5-year horizon, galantamine treatment would not result in
additional health resource use except drug cost (galantamine); 3)
the proportions of AD patients in FTC following galantamine
treatment and usual care were used to modify disease progression
over time; 4) patients continued to receive galantamine while
they are in the pre–full-time care (pre-FTC) health state and stop
galantamine when they progress to FTC health state; and 5)
galantamine had the effect to delay progression to FTC health
state for 1 year, while after 1 year, slope of decline in galantamine
group was the same as that in usual care group, regardless of
galantamine treatment. Evidence for these assumptions is pro-
vided later in the Discussion section.
Health Outcome
The main health outcome measure was the QALY [30]. This was
used as a measure of overall health-related quality of life, and
was consistent with the preferred evaluation approach for cost-
utility analysis. Beneﬁts on health-related quality of life have not
been shown in Korean literatures. Health utilities for the model
states (pre-FTC and FTC) were derived from published
Neumann et al.’s data on AD [31]. The utility of pre-FTC (0.60)
was derived from the results for patients with mild to moderate
AD, whereas utilities for severe, profound, or terminal AD were
used to calculate the utilities of FTC (0.34).
Discounting
In keeping with the previous publication on the same topic
reﬂecting the recommendation from the National Institute for
Health and Clinical Excellence (NICE) of the United Kingdom,
discount rate were 6% for future costs and 1.5% per year for
future quality of life.
Uncertainty Analyses
The multivariate probabilistic analysis is conducted to capture
uncertainty in a range of random variables (Table 1). The proba-
bilistic sensitivity analysis is based on a speciﬁed cohort of 1000
AD patients and 1000 trials using the second-order Monte Carlo
simulation in the model. Uncertainty analyses also comprised
scenario analysis against a range of other assumptions made in the
model. The considered scenarios are as follows: 1) galantamine
has the effect to delay progression to FTC health state for a
different limited time (e.g., 6months, 2 years, 3 years, and 4 years);
2) patients continue to receive galantamine treatment to death; 3)
health utility at FTC health state is 0.40, higher value than
Neumann et al.’s 0.34; 4) patients show different mortality rates
(e.g., 0%, 50%, or 150% of the mortality used in the model); 5)
different discount rates are applied (e.g., 0%, 3%, or 5%); and 6)
when effectiveness derived from the per-protocol population are
applied (e.g., control group 11.9%, galantamine group 2.7%).
Results
The primary outcome was cost per QALY gained as an Incre-
mental Cost-Effectiveness Ratio (ICER). Incremental cost was
US$5630 while incremental utility is 1.14 (Table 2). Therefore, at
base case scenario, the ICER is US$4939/QALY (Table 3). The
mean reduction in the time spent in the FTC health state
(increased time in pre-FTC) is 4.6 months over 60 months.
Further, after 60 months, 18.8% of the patient with usual care
alone remained in the pre-FTC health state, as compared to
22.7% of the galantamine treatment group (difference = 3.9%).
More than half of AD patients (56.4%) were alive after 60
months.
Uncertainty Analyses
The results of cost-effective analyses were presented in the
form of incremental cost-effectiveness scatter plot and cost-
effectiveness acceptability curves. By linking the probability that
the intervention was cost effective at different levels of the will-
ingness of the third-party payer for an additional outcome
(QALY), cost-effectiveness acceptability curves substitute for
conﬁdence intervals. According to this acceptability curve, given
a maximum acceptable ratio of US$6740 per 1 additional QALY
increase, the probability that galantamine treatment is cost-
effective compared with usual care is 1 (perfect) (Fig. 2). The
scatter plot in Figure 3 shows the results of 1000 simulations
with the incremental effectiveness plotted on the horizontal axis
Table 1 Model inputs for the cost-effectiveness analysis for galantamine compared with usual care in mild to moderately severe Alzheimer’s disease
Model input Value Distribution References
Costs
Galantamine (US$/month) 173.3 [20]
Cost per outpatient visit (US$) (SD)* 30.6 (15.3) Gamma [11,19,20,23]
Pre-FTC, cost per month (US$) (SD)* 532.3 (266.2) Gamma [11,18,19,21]
FTC, cost per month (US$) (SD)* 635.3 (317.7) Gamma [11,18,19,21]
Effectiveness
Proportion in FTC after 1-year drug treatment 0.054 (0.027) Gamma [10]
Proportion in FTC after 1-year usual care 0.222 (0.111) Gamma [10]
*Assumptions made on the standard deviation in the absence of other information.
FTC, full-time care; SD, standard deviation.
Table 2 Cost effectiveness of galantamine compared with usual care in mild to moderately severe Alzheimer’s disease
Galantamine plus usual care Usual care alone Difference
Time spent in FTC over 60 months 11.1 months 15.7 months 4.6 months
% of patients in pre-FTC at 60 months 22.7% 18.8% 3.9%
Cost (US$)* 30,567 24,937 5,630
Utility 22.91 21.77 1.14
*2007 values expressed as US dollars.
FTC, full-time care.
Cost-Effectiveness of Galantamine in Korea S51
and the incremental cost on the vertical axis. The ellipse contains
95% of the simulations. The ellipse exclusively lies in the north-
east quadrant, suggesting decision-makers should balance gain
against the cost. Further uncertainty analysis against model
assumptions and scenarios shows results that ICER values range
from US$2271 to US$8335 per QALY.
Discussion
This study reports the ICER value of galantamine in the treat-
ment of AD in Korea is an estimated US$4939 per QALY, which
should be judged “accepted.” Generally speaking, there is a
linear relationship between the Gross Domestic Product (GDP)
of a country and willingness to pay for an additional QALY. In
2007, GDP per capita was US$21,695 in Korea. This study
indicates that the use of galantamine for the treatment of mild to
moderately severe AD may be cost-effective in Korea
The cost-effectiveness of Alzheimer’s drugs is an important
topic. In the United Kingdom, revised NICE guidance suggested
that cholinesterase inhibitors were not cost-effective. Thereafter,
people in the early or severe stage of AD are currently denied the
only approved Alzheimer’s drug treatment because NICE ruled
cholinesterase inhibitors are too expensive when considering
their effectiveness [32]. Green et al. reported the cost per QALY
of galantamine in the United Kingdom was £63,103 [33], which
is more than 20 times in monetary value when comparing the
ICER values for galantamine in Korea even though these values
are not directly compared. It may be partly caused by differences
in medical, community, and residential care services provided
between Korean and the United Kingdom, different ways to
deﬁne FTC, different data for modeling, different cultural view-
points of value for money, and ﬂuctuation in currency exchange
rate. However, the same modeling methodology and assumptions
at base case scenario were applied for the cost-effectiveness
analysis.
The adapted AHEAD model for this study is different from
the original model [26,34,35]. In the previous studies of Caro
et al., the transition to FTC was modeled as a function of time
and several patient characteristics (i.e., psychotic symptoms,
extrapyramidal sign, score of cognitive scales, duration of AD,
and onset before age 65) under the assumption that FTC is
conceptually identical to the need for health-related facility care
equivalent to that provided in a nursing home setting for those
who were in more severe stage of AD [16,34,35]. However, in
this study, FTC is simply deﬁned as a state of need for care,
expressed as caregiver time more than 16 h per day.
This operational deﬁnition of FTC has several important
implications. First, FTC can be easily deﬁned as a single event as
it literally means in terms of time used, not in terms of severity of
AD or locus of care. It may make us avoid possible biases caused
by including some correlates related to FTC in the process of
developing the predictive equation to simulate FTC [16,34,35].
Strictly speaking, caregiver time may not be able to be reduced as
a function of several countable factors. For example, in addition
to the patient’s own factors (i.e., level of cognition, dysfunction,
and behavioral problem), too many other caregiver factors will
inﬂuence on the caregiver time: 1) caregiver physical and mental
health; 2) sociodemographic characteristics of caregivers (i.e.,
age, gender, level of education, duration of care till now, social
class, and income); 3) preferred health resources (i.e., home
visiting service, day care, and respite care); 4) tolerability to given
care burden; 5) general attitude toward care (i.e., optimistic or
pessimistic; feel rewarded or not rewarded); and ﬁnally 6) affec-
Table 3 Effects of the sensitivity analysis on the cost effectiveness of
galantamine compared with usual care in mild to moderately severe
Alzheimer’s disease
Results of sensitivity analysis
Cost per
QALY
Base case scenario 4939
Per-protocol population 4339
Duration of progression-delaying shift effect of galantamine
6 months 8335
2 years 3127
3 years 2515
4 years 2271
When patients continue to receive galantamine to death 6725
Assumptions on health state utilities, pre-FTC 0.60, FTC 0.40 6469
Mortality rate (% per year for all patients)
0 3417
-50% of base case 4139
+50% of base case 5638
Discount rates
No discounting 5320
3% for both costs and utility 5367
5% for both costs and utility 5438
QALY, quality-adjusted life year; FTC, full-time care.
3000 3500 4000 4500 5000 5500 6000 6500 7000
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Galantamine 24mg/day plus usual care
3620 6740
WTP per QALY (US$)
P
ro
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
, I
N
B
>
0
Figure 2 Cost-effectiveness acceptability curve for galantamine compared
with usual care. Costs are in 2007 values. INB, incremental net beneﬁt;WTP,
willingness to pay; QALY, quality-adjusted life-year.
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tion to the patient affected by AD. Too many factors can inﬂu-
ence on the caregiver time as well as related costs. Caregiver time
itself can be a robust single indicator of caregiver burden.
Second, in general, the time of 16 h a day might be maximum for
caring for patients because caregivers should spend time for their
own essential activities of daily living (i.e., sleep, eating, groom-
ing, toileting, and washing). Third, most caregivers were averse
to institutionalization and continue to provide in-home care long
after it is in their own best interests to cease [29,36]. Escalating
care demands eventually prompt caregivers to place patients in
residential care. It should not be considered that family care is a
cost-free alternative to residential care. Instead, caregivers incur
huge care burdens, including economic hardship, curtailment of
social activities, emotional strain, and psychological distress
[28,29,36]. Heavy caregiver burden will quickly convert into
tangible costs for patients and caregivers such as institutionaliza-
tion or hospitalization.
Mostly, primary endpoint of health economic studies is death.
However, death is undesired as an endpoint for AD when cost-
effectiveness analysis is performed, because use of Alzheimer’s
drugs is not supposed to extend life expectancy of people affected
by AD. Some researchers have reported no or weak association
between the long-term use of ChEIs and survival [37–39], while a
few other researchers have observed that the long-term use of
cholinesterase inhibitors (ChEIs) might lead to lower mortality
rates [40,41]. At this moment, it is rational to assume that ChEIs
do not have more than symptomatic effects, use of which will not
extend life expectancy. Therefore, more relevant surrogate end-
point should be found. Institutionalization has been most pre-
ferred surrogate endpoint because Alzheimer’s drugs are believed
to delay progression and institutionalization [5–8,42]. However,
institutionalization would be decided not only by disease progres-
sion, but also by other factors such as caregiver burden and social
situation (i.e., marital status, presence of caregiver, and ﬁnance).
Many people with severe dementia are being cared for at home
rather than in a nursing home. This is especially true in developing
countries. In Korea, 7 out of 10 persons with dementia who need
residential care were cared for at home in 2003 [43]. Operation-
ally deﬁned caregiver time more than 16 h per day as an indicator
for the FTCmay be a good candidate for surrogate endpoint in the
cost-effectiveness analysis of Alzheimer’s drugs.
The study has a number of further limitations. Financial and
personal heavy burden of caregivers is obvious, which can be
easily converted to tangible costs on the health-care system.
However, the impact of galantamine treatment on caregivers was
not considered. Expected costs of health-care use by caregivers’
diseases occurred during caring for AD patients were not
included in this model. On the other hand, even though the best
data were sought, the evidence base on the costs, effectiveness,
and health outcomes related to AD is limited. There is uncer-
tainty over parameter values used in the model, but these limi-
tations are common to the cost-effectiveness literature.
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